RxDoctor Payments Data

Brianna Schmidt, MD

Family Medicine · New Bern, NCNPI 1952808842

Payments from drug & device makers

$481in general payments, 2019–2025

Across 33 payments — averaging $14.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$85
  • Bayer$81
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$53
  • Daiichi Sankyo Inc.$46
  • GSK$42
  • Novartis$35
  • plus $138 from 9 others

What the payments were for

  • Food & beverage$481100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$481 in reported general payments places this provider in the 55th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$182,530
Medicare patients
265
Services billed
6,248

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide67$97,037
MounjaroTirzepatide60$89,874
FarxigaDapagliflozin Propanediol95$89,690
EliquisApixaban63$54,384
JardianceEmpagliflozin39$49,240
RybelsusSemaglutide26$46,883
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$30,751
Breztri AerosphereBudesonide/Glycopyr/Formoterol24$26,398
TrulancePlecanatide20$21,030
LinzessLinaclotide18$20,100
XareltoRivaroxaban11$17,856
Breo ElliptaFluticasone/Vilanterol21$10,832
SymbicortBudesonide/Formoterol Fumarate21$6,824
Tresiba Flextouch U-100Insulin Degludec13$5,765
Varenicline Tartrate12$5,210

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$85$143,92093 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$13$122,913140 claims
Lilly USA, LLCMounjaro$13$89,87460 claims
PfizerEliquis$14$54,38463 claims
GSKTrelegy Ellipta, Breo Ellipta$42$41,58264 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$53$21,03020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in New Bern

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →